Core Insights - JD Health and Hangzhou Minsheng Health Pharmaceutical Co., Ltd. signed a strategic cooperation agreement to explore patient-centered health management solutions covering the entire disease cycle [1] - The partnership aims to leverage each other's strengths in branding, products, channels, technology, and professional services to enhance the accessibility and trust in high-quality health products and services for patients [1] Group 1: Strategic Cooperation - JD Health and Hangzhou Minsheng Health Pharmaceutical will collaborate on drug development, digital marketing, and patient education to accelerate the distribution of quality health products nationwide [1] - The CEO of Hangzhou Minsheng Health Pharmaceutical emphasized the importance of JD Health's omnichannel layout and professional medical service resources in enhancing patient access to quality health resources [1] Group 2: New Product Launch - Hangzhou Minsheng Health Pharmaceutical launched a new smoking cessation drug, Varenicline Tartrate Tablets (brand name: Minsheng Lesuke®), on JD Health, featuring a 0.5mg mini tablet design for easier dosage adjustment [2] - The packaging utilizes advanced double aluminum sealing technology to ensure drug stability, and the tablet includes easy-to-tear markings for daily dosage management [2] Group 3: Industry Development - JD Health is committed to deepening industry cooperation and enhancing the scientific smoking cessation ecosystem, aiming to provide high-quality smoking cessation products and promote scientific cessation methods [3] - The company has developed a comprehensive solution for the launch of new smoking cessation drugs and aims to address common pain points faced by smoking cessation users through various initiatives [2][3]

Core Viewpoint - The article highlights the insufficient public awareness of scientific smoking cessation methods, particularly regarding cessation medications, despite the existence of effective options and guidelines from WHO [1][12]. Group 1: Smoking Cessation Medications - WHO's first clinical treatment guideline for adult smoking cessation identifies three main types of medications: varenicline, nicotine replacement therapy (NRT), and bupropion [1][12]. - Varenicline is a first-line medication with four domestic companies having approved generic versions, yet sales were below 100 million yuan last year [1][12]. - The sales of varenicline in China have not met expectations, with Pfizer's original product experiencing a significant decline due to safety concerns [1][18]. Group 2: Challenges in Smoking Cessation - Nearly 60% of smokers abandon cessation attempts due to withdrawal symptoms, with a success rate of less than 5% for those relying solely on willpower [7][8]. - The understanding of cessation medications among both smokers and healthcare professionals remains limited, contributing to low utilization rates [13][17]. - The lack of awareness and the absence of these medications in insurance coverage are identified as major barriers to effective smoking cessation [20]. Group 3: Market Trends and Opportunities - The retail market for varenicline is projected to grow significantly, with sales expected to reach 48 million yuan in 2024, reflecting a growth rate exceeding 2000% [20][21]. - Online platforms like JD Health report a more than twofold increase in sales of smoking cessation medications, indicating a shift towards digital health solutions [20]. - The market share of companies like Qianyuan Pharmaceutical in the retail sector is notably high, suggesting potential for further expansion in the smoking cessation market [20][21].

Core Viewpoint - The article highlights the challenges of quitting smoking in China, emphasizing the need for scientific methods and professional support to improve cessation success rates [1][2][3]. Group 1: Smoking Statistics and Challenges - The smoking rate among individuals aged 15 and above in China is reported at 23.2% [1]. - The success rate for individuals attempting to quit smoking on their own is less than 5% within a year [2]. - Nicotine addiction is recognized as a chronic disease, complicating the quitting process due to withdrawal symptoms such as anxiety and depression [2][3]. Group 2: Scientific Approaches to Quitting - A significant portion of smokers (87.1%) attempts to quit using nicotine replacement therapies like patches and gum, yet the usage rate of cessation medications is below 5% [3]. - The "2025 Tobacco Control and Cessation White Paper" outlines seven effective strategies for quitting smoking, including setting a quit plan and seeking professional help [3]. - The need for a collaborative effort from various sectors to provide effective health management solutions for smokers is emphasized [4]. Group 3: Industry Initiatives - JD Health, in collaboration with pharmaceutical companies, is advocating for a scientific smoking cessation management ecosystem to address public awareness and accessibility issues [4]. - The initiative includes organizing public lectures and health consultations to enhance understanding of smoking cessation [4].